United Therapeutics Stock News

MannKind (MNKD) said the U.S. Food and Drug Administration ((FDA)) has extended its deadline to May from February to review United Therapeutics'' (UTHR) new drug application ((NDA))…

United Therapeutics (UTHR) delivered earnings and revenue surprises of -37.67% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (NASDAQ:UTHR) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is $4.05 (+22.4% Y/Y) and

Let's see if United Therapeutics Corporation (UTHR) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2021 financial r

Credit Suisse argues that BioMarin Pharmaceutical <>, United Therapeutics <>, and Insmed Incorporated <> still carry further upside opportunities in 2022, despite…

United Therapeutics (UTHR) said the world''s first recipient of a genetically-modified xenotransplanted organ, developed by the company, UHeart, reached a two-week milestone.Earlier

MannKind <> is trading higher after announcing that the FDA accepted the marketing application submitted by United Therapeutics <> for Tyvaso DPI.MannKind (MNKD) shares

In a last-ditch effort to save his life, doctors at the University of Maryland Medical Center have transplanted a genetically modified pig heart into patient David Bennett, a

These seven pharmaceutical stocks could create lucrative opportunities in the new year The post 7 Pharmaceutical Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlac

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics' senior leaders will participate in a conversation hosted by J.P. Morgan biotech analyst Jessica Fye on January

United Therapeutics Corp (UTHR) shares closed today at 1.8% below its 52 week high of $217.75, giving the company a market cap of $9B. The stock is currently up 40.9% year-to-date, up 42.5% over the past 12 months, and up 49.5% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 32.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 6.5% The company's stock price performance over the past 12 months beats the peer average by 9.4% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 22.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

United Therapeutics Corp (UTHR) shares closed today at 1.3% below its 52 week high of $216.90, giving the company a market cap of $9B. The stock is currently up 41.0% year-to-date, up 42.9% over the past 12 months, and up 50.7% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 13.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 11.8% The company's stock price performance over the past 12 months beats the peer average by 15.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 24.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

United Therapeutics Corp (UTHR) shares closed today at 1.3% below its 52 week high of $216.90, giving the company a market cap of $9B. The stock is currently up 41.0% year-to-date, up 42.9% over the past 12 months, and up 50.7% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 11.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 11.8% The company's stock price performance over the past 12 months beats the peer average by 15.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 24.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

United Therapeutics Corp (UTHR) shares closed today at 1.3% below its 52 week high of $216.90, giving the company a market cap of $9B. The stock is currently up 41.0% year-to-date, up 43.3% over the past 12 months, and up 50.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 11.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 11.4% The company's stock price performance over the past 12 months beats the peer average by 14.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 24.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.